Search clinical trials for: Epoetin beta

Total 6536 results

Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

Anemia

Spain
JW Pharmaceutical

Completed

Study of Erythropoietin (EPO) Administration Schedule

Chronic Renal Failure | Anaemia

Korea, Republic of
Institut du Cancer de Montpellier - Val d'Aurelle

Terminated

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors (PLATON)

Anemia | Unspecified Adult Solid Tumor, Protocol Specific

France
University of Zurich

Unknown

Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans

Healthy

Switzerland
University of Zurich
Swiss National Science Foundation

Active, not recruiting

Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants (EpoRepair)

Intraventricular Hemorrhage of Prematurity

Switzerland, Austria
Hoffmann-La Roche

Completed

A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy

Anemia

India
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Giovanni FM Strippoli, MD

Completed

The Clinical Evaluation of the Dose of Erythropoietins Trial (CEDOSE)

Kidney Failure, Chronic

Italy
University of Washington
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) (PENUT)

Extreme Prematurity

United States
Hoffmann-La Roche

Completed

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

Anemia

Italy
Hoffmann-La Roche

Terminated

A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B

Anemia

Venezuela
Hoffmann-La Roche

Terminated

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Anemia

Venezuela
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Anemia

Belgium, Italy, Poland, Spain, Hong Kong, Canada, France, Greece, Czech Republic, Austria, Estonia, Hungary, Australia, Germany, Finland
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

Turkey
Centre Hospitalier Universitaire, Amiens
Roche Pharma AG

Completed

Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant (Neo-PDGF)

Kidney Failure

France
University Hospital, Basel, Switzerland

Completed

Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEATSTEMIPi)

Acute Myocardial Infarction

Switzerland
Hoffmann-La Roche

Completed

A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.

Anemia

Serbia
Zhengzhou University
Göteborg University; The First Affiliated Hospital of Zhengzhou University; Zhengzhou... and other collaborators

Completed

Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis

Premature Infant

China
Hoffmann-La Roche

Completed

A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis (ALTITUD)

Anemia, Kidney Disease, Chronic

Mexico
Hoffmann-La Roche

Completed

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients

Anemia

Philippines
Hoffmann-La Roche

Completed

A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia (ORION)

Anemia

Italy
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Hemodialysis Patients

Hemodialysis Patients

Japan
Hoffmann-La Roche

Completed

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Renal Insufficiency, Chronic | Anemia

United States, Spain, France, Hungary, Italy, Lithuania, Poland
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Anemia | Lung Cancer

United States
University Hospital, Limoges
Hoffmann-La Roche

Terminated

Renal Graft Function After Treatment With Erythropoietin (EPO) (FRETEP)

Ischemia

France
Hoffmann-La Roche

Withdrawn

A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Anemia

Denmark
Hoffmann-La Roche

Terminated

Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia

Anemia

Sweden
Hoffmann-La Roche

Completed

A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)

Renal Anemia of Chronic Kidney Disease

France
Hoffmann-La Roche

Completed

A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.

Anemia

Netherlands
Hoffmann-La Roche

Completed

A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

India
Hoffmann-La Roche

Terminated

A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia

Anemia

Indonesia
Hoffmann-La Roche

Completed

LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

Mexico, Colombia, Argentina, Venezuela, Brazil, Uruguay, Ecuador, Peru, Chile
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis (MERCUR)

Anemia

Germany
Hoffmann-La Roche

Terminated

A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.

Anemia

Costa Rica, Guatemala, Argentina, Brazil, Panama, Chile, Colombia, Ecuador, Peru, Venezuela
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.

Anemia

Russian Federation
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Germany
Sheri Kashmir Institute of Medical Sciences

Completed

Neuroprotective Role of Erythropoietin in Perinatal Asphyxia

Perinatal Asphyxia

India
Chugai Pharmaceutical

Completed

Correction Study of R744 in Renal Anemia Patients on Hemodialysis

Hemodialysis Patients

Japan
Hoffmann-La Roche

Completed

A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)

Kidney Disease, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia (CARISMA)

Anemia

Italy
Hoffmann-La Roche

Completed

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Renal Anemia

Belgium, Romania, Australia, France, Spain, Hungary, Italy, Poland, Germany, Russian Federation, Thailand, Ukraine
Hoffmann-La Roche

Completed

A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia

Anemia

Taiwan
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Hoffmann-La Roche

Completed

A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis

Anemia

France
Hoffmann-La Roche

Completed

STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients

Anemia

Czech Republic
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.

Anemia

Estonia, Latvia, Finland, Norway
University of Copenhagen
Rigshospitalet, Denmark

Completed

Renal Effects of Erythropoietin in Humans (EPO 2012)

Renal Effects

Denmark
University Hospital, Angers

Completed

Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C

Chronic Hepatitis C

France

3

Subscribe